CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) T-cell therapies are promising treatments for a range of cancers, offering hope to patients whose cancers have become refractory to ...

Lentiviral transduction is a popular delivery platform for applications such as CAR-T cell engineering or CRISPR-Cas9 gene editing, as it can transduce both dividing and non-dividing cells and ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more ...

CAR-T cell therapy involves extracting a ... allowing safer and more efficient gene transfer. Optimizing transduction timing: The study revealed that macrophages' gene uptake efficiency depends ...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...

Which neoadjuvant treatment is best for locally advanced esophageal cancer? a systematic review and network meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering ...